ZYME - Latest News
Zymeworks Inc. (ZYME), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $1.78B. Beta to the broader market is 1.14.
The article list below shows the most recent ZYME headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent ZYME Headlines
Theravance Stock Down 3% After Zymeworks Announces Buyout
zacks.com - Jun 30, 2026
TBPH falls after agreeing to a $929 million all-cash acquisition by Zymeworks, following a strategic review triggered by its failed ampreloxetine prog
Zymeworks Inc. (ZYME) M&A Call Transcript
seekingalpha.com - Jun 29, 2026
Zymeworks Inc.
Zymeworks Targets Long-Term Cash Generation Through Theravance Acquisition
benzinga.com - Jun 29, 2026
Zymeworks Inc. (NASDAQ:ZYME) said Monday it has agreed to acquire Theravance Biopharma Inc.
Zymeworks strikes $929 million deal for Theravance Biopharma
reuters.com - Jun 29, 2026
Drugmaker Zymeworks said on Monday it will buy Theravance Biopharma in a $929 million deal.
Zymeworks to Acquire Theravance Biopharma, Inc.
globenewswire.com - Jun 29, 2026
VANCOUVER, British Columbia, June 29, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME) (the “Company”), a biotechnology company managing a port
How News Affects ZYME Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track ZYME's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked ZYME news questions
- What is the latest ZYME news headline?
- The most recent ZYME headline (Jun 30, 2026) is "Theravance Stock Down 3% After Zymeworks Announces Buyout". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the ZYME news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What ZYME news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual ZYME options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.